Clinical strategies to enhance posttransplant immune reconstitution

Irwin D Bernstein, Richard Boyd, Marcel R M van den Brink

Research output: Contribution to journalLetterOther

Abstract

This is not the end. It s not even the beginning of the end. But it is, perhaps, the end of the beginning. Sir Winston Churchill Immune reconstitution after hematopoietic stem cell transplantation (HSCT) has been well studied in the mouse and humans, and the relationship between delayed immune reconstitution and posttransplant morbidity and mortality from infections and relapse has been well documented [1]. Whereas erythroid, myeloid, and platelet reconstitution occurs in most cases in the first weeks after HSCT and is primarily determined by engraftment of donor HSCs, B cell, and especially T cell reconstitution takes much longer, and recipients of allogeneic HSCT can have an impaired T and B cell function even years after their HSCT [2]. In recent years a number of strategies to enhance posttransplant immune reconstitution have been developed and successfully tested in preclinical models. These studies in experimental models mark the end of the beginning, and in this article we will discuss the first attempts to introduce these strategies in clinical trials with HSCT recipients.
Original languageEnglish
Pages (from-to)94 - 94
Number of pages1
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue numberS1
DOIs
Publication statusPublished - 2008

Cite this

Bernstein, Irwin D ; Boyd, Richard ; van den Brink, Marcel R M. / Clinical strategies to enhance posttransplant immune reconstitution. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. S1. pp. 94 - 94.
@article{cf2eb6afa7df4e2dad3cbf986e85ac9d,
title = "Clinical strategies to enhance posttransplant immune reconstitution",
abstract = "This is not the end. It s not even the beginning of the end. But it is, perhaps, the end of the beginning. Sir Winston Churchill Immune reconstitution after hematopoietic stem cell transplantation (HSCT) has been well studied in the mouse and humans, and the relationship between delayed immune reconstitution and posttransplant morbidity and mortality from infections and relapse has been well documented [1]. Whereas erythroid, myeloid, and platelet reconstitution occurs in most cases in the first weeks after HSCT and is primarily determined by engraftment of donor HSCs, B cell, and especially T cell reconstitution takes much longer, and recipients of allogeneic HSCT can have an impaired T and B cell function even years after their HSCT [2]. In recent years a number of strategies to enhance posttransplant immune reconstitution have been developed and successfully tested in preclinical models. These studies in experimental models mark the end of the beginning, and in this article we will discuss the first attempts to introduce these strategies in clinical trials with HSCT recipients.",
author = "Bernstein, {Irwin D} and Richard Boyd and {van den Brink}, {Marcel R M}",
year = "2008",
doi = "10.1016/j.bbmt.2007.10.003",
language = "English",
volume = "14",
pages = "94 -- 94",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier",
number = "S1",

}

Clinical strategies to enhance posttransplant immune reconstitution. / Bernstein, Irwin D; Boyd, Richard; van den Brink, Marcel R M.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. S1, 2008, p. 94 - 94.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Clinical strategies to enhance posttransplant immune reconstitution

AU - Bernstein, Irwin D

AU - Boyd, Richard

AU - van den Brink, Marcel R M

PY - 2008

Y1 - 2008

N2 - This is not the end. It s not even the beginning of the end. But it is, perhaps, the end of the beginning. Sir Winston Churchill Immune reconstitution after hematopoietic stem cell transplantation (HSCT) has been well studied in the mouse and humans, and the relationship between delayed immune reconstitution and posttransplant morbidity and mortality from infections and relapse has been well documented [1]. Whereas erythroid, myeloid, and platelet reconstitution occurs in most cases in the first weeks after HSCT and is primarily determined by engraftment of donor HSCs, B cell, and especially T cell reconstitution takes much longer, and recipients of allogeneic HSCT can have an impaired T and B cell function even years after their HSCT [2]. In recent years a number of strategies to enhance posttransplant immune reconstitution have been developed and successfully tested in preclinical models. These studies in experimental models mark the end of the beginning, and in this article we will discuss the first attempts to introduce these strategies in clinical trials with HSCT recipients.

AB - This is not the end. It s not even the beginning of the end. But it is, perhaps, the end of the beginning. Sir Winston Churchill Immune reconstitution after hematopoietic stem cell transplantation (HSCT) has been well studied in the mouse and humans, and the relationship between delayed immune reconstitution and posttransplant morbidity and mortality from infections and relapse has been well documented [1]. Whereas erythroid, myeloid, and platelet reconstitution occurs in most cases in the first weeks after HSCT and is primarily determined by engraftment of donor HSCs, B cell, and especially T cell reconstitution takes much longer, and recipients of allogeneic HSCT can have an impaired T and B cell function even years after their HSCT [2]. In recent years a number of strategies to enhance posttransplant immune reconstitution have been developed and successfully tested in preclinical models. These studies in experimental models mark the end of the beginning, and in this article we will discuss the first attempts to introduce these strategies in clinical trials with HSCT recipients.

UR - http://download.journals.elsevierhealth.com/pdfs/journals/1083-8791/PIIS1083879107005319.pdf

U2 - 10.1016/j.bbmt.2007.10.003

DO - 10.1016/j.bbmt.2007.10.003

M3 - Letter

VL - 14

SP - 94

EP - 94

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - S1

ER -